NAMI-A

Cat. No.: HY-19376
CAS No.: 201653-76-1
Molecular Formula: C₅H₁₀Cl₄N₂ORuS . C₃H₄N₂ . H
Molecular Weight: 458.18
Target: FAK
Pathway: Protein Tyrosine Kinase/RTK
Storage: Powder
-20°C 3 years
4°C 2 years
In solvent
-80°C 6 months
-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

H₂O : 8.28 mg/mL (18.07 mM; Need ultrasonic and warming)

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>Mass 1 mg</th>
<th>Mass 5 mg</th>
<th>Mass 10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.1825 mL</td>
<td>10.9127 mL</td>
<td>21.8255 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4365 mL</td>
<td>2.1825 mL</td>
<td>4.3651 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2183 mL</td>
<td>1.0913 mL</td>
<td>2.1825 mL</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration. In vitro: NAMI-A can significantly affect tumor cells with metastatic ability. The half lifetime of NAMI-A elimination from the lungs is longer than for liver, kidney, and primary tumor. NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metallo-proteinases MMP-2 and MMP-9 at micromolar concentrations. [1] The ruthenium drug NAMI-A inhibits the adhesion and migration of colorectal cancer cells. NAMI-A decreases α5β1 integrin expression and FAK auto-phosphorylation on Tyr 397. [2]

REFERENCES